Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 8,037 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: RNA Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

NCT00376090
View directory record Official record
Conditions
HIV Infections
Interventions
MVA-CMDR, Placebo
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 40 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 30, 2026, 6:21 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Evaluation of the INDICAID™ COVID-19 Rapid Antigen Test

NCT04904510
View directory record Official record
Conditions
Covid19
Interventions
INDICAID™ COVID-19 Rapid Antigen Test
Diagnostic Test
Lead sponsor
University of California, Los Angeles
Other
Eligibility
5 Years and older
Enrollment
297 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 30, 2026, 6:21 PM EDT
Completed Phase 2 Interventional Results available

Famotidine vs Placebo for the Treatment of Non-Hospitalized Adults With COVID-19

NCT04724720
View directory record Official record
Conditions
Covid-19
Interventions
Famotidine, Placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 30, 2026, 6:21 PM EDT
Completed Not applicable Interventional

Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections

NCT00002024
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 6:21 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome

NCT02996448
View directory record Official record
Conditions
Autosomal-dominant Hyper-IgE Syndrome
Interventions
NDV-3A
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 30, 2026, 6:21 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia

NCT04652726
View directory record Official record
Conditions
Familial Hypercholesterolemia - Heterozygous
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Tucson, Arizona • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 30, 2026, 6:21 PM EDT
Completed Phase 1 Interventional

A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients

NCT00002248
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Cryptosporidium Immune Whey Protein Concentrate (Bovine)
Drug
Lead sponsor
Univax Biologics Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 6:21 PM EDT
Terminated Phase 2 Interventional Results available

Non-comparative Trial of the Combination of HCQ and AZI in the Treatment of ICU Patients

NCT04458948
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine, Azithromycin
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 30, 2026, 6:21 PM EDT
Completed Phase 3 Interventional Results available

LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780268
View directory record Official record
Conditions
COVID-19
Interventions
LY3819253, Placebo, Remdesivir
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
42
States / cities
Tucson, Arizona • Fresno, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 30, 2026, 6:21 PM EDT
Completed Phase 2 Interventional Results available

D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults

NCT01565850
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
D/C/F/TAF, DRV, COBI, FTC/TDF, D/C/F/TAF Placebo, DRV Placebo, COBI Placebo, FTC/TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
43
States / cities
Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 30, 2026, 6:21 PM EDT
Completed Early Phase 1 Interventional

Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals

NCT01836068
View directory record Official record
Conditions
HIV
Interventions
Enfuvirtide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 30, 2026, 6:21 PM EDT
Completed Phase 2 Interventional

ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past

NCT00004582
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir, Efavirenz
Drug
Lead sponsor
ViRx
Industry
Eligibility
0 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 6:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs

NCT00017758
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity, Lipodystrophy
Interventions
Pravastatin sodium, Simvastatin, Atorvastatin calcium, Nelfinavir mesylate, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
10
States / cities
Stanford, California • Denver, Colorado • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2006 · Synced Oct 30, 2026, 6:21 PM EDT
Active, not recruiting No phase listed Observational

Post Acute Sequelae of COVID-19

NCT04964115
View directory record Official record
Conditions
Covid19, Sars-CoV-2 Infection, Dyspnea Caused by 2019-nCoV, COVID-19 Acute Respiratory Distress Syndrome, Pulmonary Fibrosis
Interventions
Cohort study
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 30, 2026, 6:21 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

An Imaging Trial of the Distribution of Topical Gel Formulations in the Human Vagina

NCT00214747
View directory record Official record
Conditions
HIV Infections
Interventions
Vehicle gel formulations
Drug
Lead sponsor
Biosyn
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 25, 2005 · Synced Oct 30, 2026, 6:21 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine

NCT01943825
View directory record Official record
Conditions
Dengue, Dengue Fever, Dengue Hemorrhagic Fever
Interventions
CYD Dengue Vaccine, Japanese Encephalitis Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Oct 30, 2026, 6:21 PM EDT
Withdrawn Not applicable Interventional

Effects of Growth Hormone in Chronically Ill Children

NCT00286689
View directory record Official record
Conditions
Hurler Syndrome, Cerebral Palsy, Juvenile Rheumatoid Arthritis, Crohn Disease, HIV Infections
Interventions
Growth Hormone, Whole body Protein turnover, DEXA scan
Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
3 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2018 · Synced Oct 30, 2026, 6:21 PM EDT
Completed Not applicable Interventional Results available

COVID-19 Vaccination Take-Up

NCT04867174
View directory record Official record
Conditions
Covid19, Vaccination
Interventions
Financial incentives, Convenient scheduling link, Race concordant, Gender concordant
Behavioral
Lead sponsor
National Bureau of Economic Research, Inc.
Other
Eligibility
18 Years and older
Enrollment
2,701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Martinez, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Oct 30, 2026, 6:21 PM EDT
Completed Phase 1 Interventional

Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome

NCT00000726
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Foscarnet sodium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 30, 2026, 6:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Drug Interaction Study With Protease Inhibitors

NCT00774735
View directory record Official record
Conditions
Healthy Subjects, Infection, Human Immunodeficiency Virus
Interventions
GSK1349572
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Oct 30, 2026, 6:21 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Rapid Vaccination of Hard-To-Reach Populations

NCT00155974
View directory record Official record
Conditions
Influenza
Interventions
Community-based vaccine outreach intervention
Biological
Lead sponsor
The New York Academy of Medicine
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2006 · Synced Oct 30, 2026, 6:21 PM EDT
Completed Not applicable Interventional

A Study of Isoprinosine in Patients With Lymph Node Disease

NCT00002297
View directory record Official record
Conditions
Lymphatic Disease, HIV Infections
Interventions
Inosine pranobex
Drug
Lead sponsor
Newport Pharmaceuticals International
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 6:21 PM EDT
Completed No phase listed Observational

A Comparison of Two Anti-HIV Treatment Plans

NCT00005915
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
21
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2013 · Synced Oct 30, 2026, 6:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Young Adult Influenza Vaccine Immunogenicity Substudy

NCT00170508
View directory record Official record
Conditions
Influenza
Interventions
Fluzone®
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 30, 2026, 6:21 PM EDT